- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT02841293
Custo-utilidade de duas estratégias de reconstrução perineal após ressecção abdominoperineal para carcinoma anorretal (GRECCAR-9)
Avaliação de custo-utilidade de duas estratégias de reconstrução perineal após ressecção abdominoperineal para carcinoma anorretal: preenchimento perineal com telas biológicas versus fechamento primário da ferida perineal
Abdominoperineal resection performed for anorectal tumors leaves a large pelvic and perineal defect causing a high rate of morbidity of the perineal wound (40 - 60 %). Biological meshes offer possibility for a new standard of perineal wound reconstruction. Perineal filling with biological mesh is expected to increase quality of life by reducing perineal morbidity.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Perineal wound problems after abdominoperineal resection (APR) in the context of cancer are frequent. These types of resection problems occur because of wound complications caused by large perineal defects. Indeed, perineal wound complications, perineal abscess, wound dehiscences, chronic fistulas and sinuses lengthen the hospital stays. Futhermore, the standardization of the surgery since the late 2000s and the extralevator technique lead a larger defect and increase i perineal complications.
Several strategies are used to decrease the complication rate. Closure by direct approximation of the pelvic muscles leads to a rate of major complication up to 57% depending on the series. Musculocutaneous flaps help to reduce this rate (16- 65%) but they generate their own morbidity, require experience and increase the costs of care. Finally, the use of biologic meshes since the beginning of 2010 seems to have improve the healing process. However, results are still variable and the only randomized study comparing direct closure and mesh closure showed no significant results at one year. Another ongoing randomized trial is comparing gluteus maximus flap to mesh closure and focusing on physical performances.
This increase in post-operative complications and their consequences causes an increase in costs. In addition, they affect the patients' quality of life and lead to a loss of productivity. From an oncological point of view, perineal scarring problems can cause a delay in the adjuvant therapeutic sequence. Few studies have highlighted the efficiency of perineal wound complications, using cost-effectiveness analyses. In order to clarify the best strategy comparing primary and mesh closure in term of cost effectiveness on perineal healing after ELAPE, we designed this randomized controlled trial.
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
-
Amiens, França
- Amiens University Hospital
-
Angers, França
- Angers University Hospital
-
Besançon, França
- Besançon University Hospital
-
Bordeaux, França
- Bordeaux University Hospital
-
Bordeaux, França, 33000
- Clinique Tivoli Ducos
-
Caen, França
- Caen University Hospital
-
Clermont-Ferrand, França
- Clermont-Ferrand University Hospital
-
Grenoble, França
- Grenoble University Hospital
-
Lille, França
- CHRU Lille
-
Lille, França
- Centre Oscar Lambret
-
Lyon, França
- Lyon University Hospital
-
Marseille, França, 13915
- Hôpitaux Universitaires de Marseille Nord
-
Marseille, França
- Paoli Calmettes Institut
-
Nancy, França
- Institut de Cancérologie de Lorraine
-
Nancy, França
- Nancy University Hospital
-
Nantes, França
- Nantes University Hospital
-
Paris, França
- Saint-Antoine Hospital
-
Rouen, França
- Rouen University Hospital
-
Strasbourg, França, 67200
- Hôpital de Hautepierre (Hôpitaux Universitaires de Strasbourg)
-
Toulouse, França, 31059
- University Hospital of Toulouse
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
-
Age ≥ 18
-
Eastern Cooperative Oncology Group performance status score of 2 or less
-
Histologically proven rectal adenocarcinoma or anal canal epidermoïd carcinoma
-
Abdominoperineal resection indication after multidisciplinary team discussion:
- for rectal adenocarcinoma: circumferential MRI margin equal or less than 1 mm from closest tumoral structure and a striated muscular layer (levator ani or external anal sphincter)
- for epidermoid carcinoma: residual or recurrent tumour after chemoradiotherapy.
-
Voluntary written informed consent
-
Patients with social security insurance or equivalent social protection
Exclusion Criteria:
- T4 tumour needing a surgical extensive resection with reconstruction by a musculocutaneous flap
- Metastasis disease deemed unresectable with curative intent
- Previous pelvic radiotherapy for another disease than the rectal or anal cancer
- Immunosuppressive drugs treatment
- Uncontrolled diabetes (glycosylated hemoglobin (HbA1c) > 8 % despite adequate therapy)
- Patient under juridical protection.
- Sensitivity to porcine derived products.
- Enrolment in trial with overlapping primary endpoint.
- Pregnant women
- Breastfeeding women
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Dobro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Arm with biological mesh
The intervention consists of perinal reconstruction using biological mesh (Cellis prosthesis from Meccellis Biotech, reference C1015E size 10x15cm) |
The intervention consists of suturing a biological mesh in the pelvic floor defect. The mesh will be sutured at each side of the coccyx or distal sacrum and directly to the residual pelvic floor muscle and fascia by using interrupted or continuous hand-sewn sutures with an appropriate amount of tension. The mesh that will be used is the Cellis prosthesis from Meccellis Biotech, reference C1015E which size is 10x15cm. |
|
Comparador Ativo: Arm with primary perineal wound closure
The intervention consists of perinal reconstruction by primary perineal wound closure |
The intervention consists of stitching the ischioanal and subcutaneous fat using interrupted Vicryl sutures in one or two layers similar to primary perineal closure |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Incremental Cost-Utility Ratio (ICUR)
Prazo: At 12 months
|
The primary endpoint in this study is based on the assessment of the incremental cost-utility ratio at 1 year, from the collective perspective between biological mesh perineal reconstructions versus. primary perineal closure in patients operated for anorectal carcinoma with proven rectal adenocarcinoma or anal canal epidermoid carcinoma. |
At 12 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Perineal wound healing
Prazo: At 1, 3, 6, 9 and 12 months
|
The perineal wound healing will be assessed using the Southampton wound assessment scale (6-point scale ranging from 0=normal healing to V=deep or severe wound infection) |
At 1, 3, 6, 9 and 12 months
|
|
Pain intensity
Prazo: From date of randomization until the date of study participation end of patient, assessed up to 12 months
|
assessed on an 11-point Numeric Rating Scale (NRS) at baseline before surgical procedure and at least 3 times a day during hospital stay. Thereafter, patients will rate their pain intensity in a patient subject diary every day and immediately before each use of pain medication |
From date of randomization until the date of study participation end of patient, assessed up to 12 months
|
|
Health related Quality of life
Prazo: 1 month, 3 months, 6 months, 9 months, 12 months
|
Health related quality of life will be assessed using the EuroQOL EQ-5D-5L questionnaire |
1 month, 3 months, 6 months, 9 months, 12 months
|
|
Perineal complications
Prazo: Daily during hospitalization and at 1, 3, 6, 9 and 12 months after surgery
|
Perineal complications include:
|
Daily during hospitalization and at 1, 3, 6, 9 and 12 months after surgery
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Etienne BUSCAIL, MD, University Hospital of Toulouse
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimado)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Outros números de identificação do estudo
- RC31/16/7940
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .